Nine Diagnostics is participating in the Spring 2026 DRIVE Accelerator Biomarkers and Diagnostics track, run by SCbio in partnership with MassBio. This program brings together emerging companies developing next-generation diagnostic and biomarker technologies, alongside industry mentors and ecosystem partners focused on accelerating clinical translation.
Nine Diagnostics participated in the BioTools Innovator pitch event, a competitive platform spotlighting emerging companies building enabling technologies for life sciences and diagnostics. BioTools Innovator is recognized for elevating high-impact tool and platform companies that can accelerate research workflows and downstream clinical translation.
Nine Diagnostics was selected to present at the Foundation for the NIH (FNIH) Biomarkers Consortium 20th Anniversary Symposium in Rockville, Maryland — a leading forum convening senior leaders across academia, industry, and government to advance biomarker science. This selection reflects growing recognition of our platform within the broader biomarker ecosystem and our alignment with consortium-driven efforts to accelerate clinical validation and adoption.
Nine Diagnostics and Orbits Oncology have executed a Letter of Intent (LOI) to jointly develop a next-generation precision oncology diagnostics platform. This collaboration brings together two complementary, cutting-edge systems: Nine’s nanosensor-based molecular fingerprinting platform—which captures integrated disease signals directly from blood—and Orbit Oncology’s organoid-based functional drug-response platform, which measures how a patient’s tumor responds to therapies ex vivo. Together, they enable a closed-loop view of disease state and therapeutic efficacy.
Nine Diagnostics co-founders Daniel Heller and Mijin Kim are part of the Weill Cornell Medicine team led by Lish Ndhlovu contributing to the ARPA-H LIGHT program. This program focuses on advancing the ability to measure and interpret signals from the lymphatic system — a historically under-characterized but critical component of human biology — using AI-enabled nanosensor technologies.
We’re excited to highlight a recent publication from the lab of Nine Diagnostics co-founder Daniel Heller: “Machine perception liquid biopsy identifies brain tumours via systemic immune and tumour microenvironment signature,” published in Nature Nanotechnology (December 2025).
Nine Diagnostics has been selected to join Creative Destruction Lab (CDL) — a highly selective, university-backed deep tech program founded at the University of Toronto Rotman School of Management. CDL is not a traditional accelerator. Companies advance by hitting rigorous technical and commercial milestones, working directly with top-tier investors, serial entrepreneurs, and domain experts — many of whom are active capital allocators who have built and exited companies at scale. Acceptance rates run at approximately 3–5%, spanning pre-seed through Series A companies across AI, biotech, quantum, and energy.
Nine Diagnostics graduated from the BrightEdge accelerator program, culminating in a Demo Day presentation highlighting our progress building a nanosensor-enabled, machine learning-driven diagnostic platform for oncology. BrightEdge, the impact investment and innovation arm of the American Cancer Society, supports companies advancing innovations across prevention, detection, and treatment to improve cancer outcomes.
Nine Diagnostics was selected to present at Biotech Investor Day, a curated forum hosted by LabCentral connecting high-potential biotech and diagnostics companies with leading investors and strategic partners — including Johnson & Johnson, Pfizer, Eli Lilly, Merck, Novartis, and other top-tier life sciences organizations.
Nine Diagnostics co-founder Dr. Daniel Heller was featured in Women’s Health Magazine discussing why ovarian cancer remains so difficult to detect and how AI-enabled nanosensor technology could change the story. His research highlights the urgent funding gap in women’s health and demonstrates how nanosensors paired with AI can reveal hidden molecular “fingerprints” in blood, offering earlier and more accurate detection than current tools. This thought leadership underscores both the challenge and the promise of building next-generation diagnostics — the same vision driving Nine Diagnostics.
Why It's Hard To Detect Ovarian Cancer, According To Researchers
Nine Diagnostics co-founder and CEO Dr. Freddy T. Nguyen has been named a 2025 Scholar in Diagnostic Excellence by the National Academy of Medicine. This honor recognizes his leadership in advancing a patient-centered framework for diagnostic technology development, addressing challenges in bias, validation, and clinical implementation. His selection underscores both his national thought leadership and Nine Diagnostics’ mission to transform how medicine detects and treats disease.
Nine Diagnostics was selected to present at the 2025 MIT Health Science Forum, hosted by the MIT Industrial Liaison Program (ILP) and MIT Startup Exchange. Held on May 8, 2025, the forum convened MIT researchers, global industry leaders, and select startups to showcase cutting-edge developments at the intersection of science, technology, and health.
The event focused on five key areas shaping the future of healthcare:
AI for biomolecular modeling
Biomanufacturing for cell and gene therapies
Drug delivery
Precision oncology
Advanced diagnostics
Nine Diagnostics presented its AI-powered nanosensor platform, which enables real-time insights into disease biology using small-volume patient samples. The technology supports both early detection and treatment monitoring by integrating multidimensional data—including molecular signals, patient demographics, and clinical context—into a unified decision support framework.
The forum provided an opportunity for thought leaders and startups to engage in cross-sector dialogue, explore translational partnerships, and accelerate innovation across biomedical domains. Being selected to present reflects Nine Diagnostics’ leadership in advancing precision diagnostics and its alignment with MIT’s mission to drive impactful healthcare innovation.
Learn more about the event here: MIT ILP Health Science Forum 2025
Nine Diagnostics, a leader in AI-enabled nanosensor technology, has been selected to participate in the American Cancer Society’s BrightEdge Entrepreneurs Program, a highly selective initiative designed to accelerate the most promising oncology-focused startups. This selection marks another significant milestone for Nine Diagnostics as it continues to drive innovation in cancer treatment selection, dosing, optimization, and monitoring.
Nine Diagnostics Joins American Cancer Society’s BrightEdge Entrepreneurs Program
“What we’d like to do is triage all gynaecological disease – so when someone comes in with a complaint, can we give doctors a tool that quickly tells them it’s more likely to be a cancer or not, or this cancer than that.” -Daniel Heller
Building Novel Solutions for Women's Health
Leading Dutch and U.S. companies are joining forces to develop groundbreaking diagnostic tools and treatments in gynecological health.
The collaboration is supported by the Netherlands Innovation Network in Boston - Dutch Ministry of Economic Affairs.
Nine Diagnostics is proud to announce its acceptance into the latest cohort of the Merck Digital Sciences Studio (MDS Studio), a digital accelerator designed to enable the next generation of technologies for drug discovery and development, including artificial intelligence and machine learning. MDS Studio was founded to offer support for early-stage biomedical startups providing strategic guidance, direct investment, and connection opportunities within Merck.
Nine Diagnostics Selected for Merck Digital Sciences Studio Cohort 3
Nine Diagnostics, a leader in cutting-edge medical diagnostics, is honored to announce that it has been awarded the Novo Nordisk Golden Ticket for a residency at LabCentral, hosted by the Novo Nordisk Bio Innovation Hub. This incredible opportunity is a significant milestone for the company, reinforcing its commitment to improving healthcare through advanced technologies that enable faster, more personalized diagnostics.
Nine Diagnostics Wins Novo Nordisk Golden Ticket for LabCentral Residency
